ACADIA Pharmaceuticals Inc.
ACAD
Pozycja w akcjach
#4429
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Cena akcji
$20.16
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$3.47B
Zmiana (1 dzień)
-1.35%
Zmiana (1 rok)
-5.73%
Kraj
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)
Kategoria
Healthcare
Historia ceny akcji dla ACADIA Pharmaceuticals Inc. (ACAD)
Najwyższa cena zamknięcia: $19.68 dnia 2026-10-01
Najniższa cena zamknięcia: $6.66 dnia 2004-05-01
Najniższa cena zamknięcia: $6.66 dnia 2004-05-01
Historia cen akcji firmy ACADIA Pharmaceuticals Inc. od 2004 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | -10.45% |
| 2025 | 55.58% |
| 2024 | -35.30% |
| 2023 | 74.02% |
| 2022 | -32.82% |
| 2021 | -57.69% |
| 2020 | 18.76% |
| 2019 | 165.62% |
| 2018 | -42.16% |
| 2017 | 8.65% |
| 2016 | -22.24% |
| 2015 | 11.41% |
| 2014 | 29.97% |
| 2013 | 416.58% |
| 2012 | 328.70% |
| 2011 | 23.06% |
| 2010 | -30.48% |
| 2009 | 14.05% |
| 2008 | -90.54% |
| 2007 | 30.89% |
| 2006 | -8.44% |
| 2005 | 48.01% |
| 2004 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.63 | -3.92% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
